Express Pharma

ACTA Down, But what next?

The EU parliament has rejected the Anti-Countefeiting Trade Agreement (ACTA) but there are other similar moves to restrict free…

Moving with the market

Viveka Roychowdhury reports on the successful right sizing of strategies by both pharma MNCs and their Indian counterparts

Nurturing India’s small biotech

With India's DBT committing 30 per cent of its budget to PPPs, will these fund an ecosystem for small and medium sized companies…

Soaring High

Indian pharmaceutical companies in order mark its presence in the international markets, need to focus on regions having high…

Safer paths to greener pastures

With World Environment Day fast approaching, Usha Sharma analyses the pharma industry's measures to preserve the environment and…

M&A or MIA?

After witnessing watershed deals in the past few years, the M&A scenario in India seems to be MIA: Missing in Action. However,…

Beyond The Ban

The Government of India recently banned the use of serology-based test kits for diagnosis of tuberculosis. But this will translate…